Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis Reduces Production Jobs …
by Michael McCoy
April 29, 2013
| A version of this story appeared in
Volume 91, Issue 17
Novartis will cut about 300 positions at its Lincoln, Neb., manufacturing facility, or 40% of the plant’s workforce, over the next two years. The Swiss drugmaker says the reduction is part of an effort to decrease complexity at the facility, which will now focus only on solid and powder forms of three products. FDA shut down the Lincoln plant in December 2011 after uncovering numerous safety problems. Novartis says it has remedied all manufacturing concerns and is now shipping Sentinel, a flea control product for dogs that is produced there.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X